Reuters logo
21 天内
BRIEF-Cara Therapeutics announces top-line results from phase 2B trial
2017年6月29日 / 晚上8点27分 / 21 天内

BRIEF-Cara Therapeutics announces top-line results from phase 2B trial

1 分钟阅读

June 29 (Reuters) - Cara Therapeutics Inc:

* Cara Therapeutics announces top-line results from phase 2B trial of oral CR845 in chronic pain patients with osteoarthritis of the hip or knee

* Cara Therapeutics Inc - all tablet strengths well tolerated over eight-week treatment period

* Cara Therapeutics Inc - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose

* Cara Therapeutics Inc - statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below